Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKST4290 in Parkinson's Disease
NCT04369430Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Jan 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AKST4290 with Placebo (2 arms). Primary endpoint: Change in Motor Function During Levodopa Withdrawal (MDS-UPDRS Part 3) at 12 weeks. Started Jan 2020; status: completed.
02
Drugs
BI 144807
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04369430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369430.